Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers (NLG2111)
A Phase 1, Randomized Trial to Evaluate the Pharmacokinetics and Safety of Single Ascending Doses of Indoximod HCl (F2) Tablets (Part 1) and to Compare the Oral Bioavailability of Indoximod Cl (F2) Tablets and Indoximod Free Base Capsule Formulations and the Effect of Food (Part 2) in Healthy Male Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Secaucus, New Jersey, United States, 07407
- Frontage Clinical Services, Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-smoker for at least 3 months
- BMI within 18 to 30 kg/m2
- Able to speak, read, and understand English or Spanish
Exclusion Criteria:
- Clinically significant cardiac, pulmonary, hepatic or renal disease
- History of substance abuse or alcohol dependence within past 2 years
- Inability to fast for a minimum of 14 hours
- Inability to swallow large capsules/tablets
- Pending legal charges or is on probation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part 1: Single Ascending Dose
|
The doses will be ascending per cohort from 600 mg to 2400 mg
The matching placebo doses will be ascending per cohort from 1 to 4 tablets
Single oral administration of 1200 mg
|
|
Experimental: Part 2: Bioavailability and Food Effect
|
The doses will be ascending per cohort from 600 mg to 2400 mg
Single oral administration of 1200 mg
Single oral administration of 1200 mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve
Time Frame: up to 20 Days
|
Part 2
|
up to 20 Days
|
|
Pharmacokinetics: Serum concentrations (Cmax/Steady State)
Time Frame: up to 20 Days
|
Part 2
|
up to 20 Days
|
|
Pharmacokinetics: Serum concentrations (Cmax/Steady State)
Time Frame: up to 4 Days
|
Part 1
|
up to 4 Days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients with adverse events
Time Frame: up to 18 Days
|
Part 1
|
up to 18 Days
|
|
Percentage of patients with adverse events
Time Frame: up to 36 Days
|
Part 2
|
up to 36 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Eugene Kennedy, MD, NewLink Genetics Inc
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NLG2111
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.